These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27169618)

  • 1. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underestimation of N-glycoPEGylated factor IX one-stage clotting activity owing to contact activator-impaired activation.
    Persson E; La Cour Christoffersen C
    Res Pract Thromb Haemost; 2017 Oct; 1(2):259-263. PubMed ID: 30046695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system.
    Duboscq C; Sueldo E; Rosa C; Zirpoli M; Ceresetto J; Baques A; Arias M
    Int J Lab Hematol; 2024 Feb; 46(1):128-134. PubMed ID: 37704365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.
    Sørensen MH; Andersen S; Ezban M
    Haemophilia; 2015 Nov; 21(6):832-6. PubMed ID: 25929807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin.
    Persson E; Foscolo T; Hansen M
    Res Pract Thromb Haemost; 2019 Jan; 3(1):114-120. PubMed ID: 30656284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
    Waters EK; Hilden I; Sørensen BB; Ezban M; Holm PK
    J Thromb Haemost; 2015 Nov; 13(11):2041-52. PubMed ID: 26340413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
    Østergaard H; Bjelke JR; Hansen L; Petersen LC; Pedersen AA; Elm T; Møller F; Hermit MB; Holm PK; Krogh TN; Petersen JM; Ezban M; Sørensen BB; Andersen MD; Agersø H; Ahmadian H; Balling KW; Christiansen ML; Knobe K; Nichols TC; Bjørn SE; Tranholm M
    Blood; 2011 Aug; 118(8):2333-41. PubMed ID: 21700771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
    Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
    Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
    Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
    J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
    Negrier C; Knobe K; Tiede A; Giangrande P; Møss J
    Blood; 2011 Sep; 118(10):2695-701. PubMed ID: 21555744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).
    Sternebring O; Gabel-Jensen C; Jacobsen H; Benie AJ; Bjørnsdottir I
    BioDrugs; 2019 Dec; 33(6):673-681. PubMed ID: 31549312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.